Gaudium IVF and Women Health LtdQ1 FY27
Gaudium IVF and Women Health Ltd Q1 FY27 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Price: ₹114P/E: 38.9Market Cap: ₹953 CrSector: Healthcare Services
Management growth scorecard
Revenue
Category 2
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
Yes
1 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 2- →The company expects a revenue growth guidance of around 30% year-on-year for FY27, consistent with historical performance.
- →Q1 revenue grew by 9%, influenced by typical seasonal slowdowns in IVF treatments during quarter 1 due to heat-related patient behavior and ongoing integration of new technology and hubs.
- →Full-year growth target of 30% is supported by new hubs becoming operational, especially South Extension in New Delhi and upcoming locations.
- →The flagship Janakpuri center continues to grow roughly at 30% year-on-year.
- →Expansion includes opening 10 new hubs in FY27 and a women’s hospital in Lucknow (expected to commercialize in FY28-29).
- →Average revenue per patient, excluding low-value services, is approximately ₹4 lakhs.
- →The company is confident of maintaining EBITDA and PAT margins similar to FY26 by year-end, after accounting for upfront expansion costs.
Margin guidance
Category 3- →The company guides for a 30% year-on-year revenue growth for FY27, consistent with its historical performance.
- →Adjusted EBITDA margins are expected to be sustained at levels similar to FY26 by the end of FY27.
- →The current quarter's margin compression is attributed to a one-time heavy marketing push for AI tools SiD and ERICA; excluding these, margins align with steady-state operating profile.
- →Profit After Tax (PAT) and EBITDA are projected to grow in line with revenue growth, supported by higher patient volumes and clinical advancements.
- →Expansion of IVF hubs (27 planned) and integration of AI technologies are key drivers for future earnings growth.
- →The company maintains a debt-light structure, supporting financial flexibility for expansion without compromising profitability.
- →Earnings Per Share (EPS) growth is implied to follow the upward revenue and profit trajectory, though specific EPS guidance is not provided.
3 more insights locked — sign up free to unlock
Fundraise plans
- →No current or planned fundraising through debt or equity is mentioned.
- →The company maintains a debt-light structure with a low consolidated debt-to-equity ratio of approximately 0.04 times.
- →Expansion plans, including the capex of ₹25 crores for new IVF hubs and ₹15 crores for the Gaudium Women Hospital in Lucknow, are funded primarily through IPO proceeds and internal accruals.
- →Specifically, the Lucknow hospital project will be financed using internal accruals, not IPO proceeds.
- →The company emphasizes financial discipline and intends to fund its expansion without increasing debt, leveraging its strong balance sheet and cash reserves.
Order book
The transcript does not explicitly mention any current or expected order book or pending orders for Gaudium IVF and Women Health Limited. However, relevant insights related to growth and expansion include:
- The company is focused on expanding with 19 new IVF centers planned.
- Operations for one hub have commenced, with two more hubs expected to start within a month.
- The company anticipates adding three new hubs this quarter.
- Confident in achieving 30% year-on-year revenue growth in FY27, consistent with historical performance.
- Aggressive marketing push on new AI technologies (SiD and ERICA) nationwide to drive growth.
- Expansion strategy aims at consolidating the market amidst new ART regulations.
- Focus on integrating technology and new centers to boost future revenue streams.
No specific orderbook or pending order figures were disclosed in the call.
Capex plans
Yes- →**Current FY27 Capex:** ₹25 crores planned for 10 new IVF hubs, averaging ₹2.5 crores per hub (₹1 crore construction + ₹1.5 crores lab machinery). Funded mainly through IPO proceeds and internal accruals.
- →**Gaudium Women Hospital, Lucknow:** Board approved up to ₹15 crores for project cost, to be incurred progressively over setup and commissioning in FY28-FY29. Funded mainly through internal accruals, not IPO proceeds.
- →**Capex Strategy:** Focus on a debt-light, capital-efficient, asset-light hub-and-spoke rollout.
- →**Expansion Plan:** Includes 19 new IVF centres and continued ramp-up of new hubs.
- →**Financial Position:** Robust and debt-light balance sheet post-IPO, with ₹8.12 crores cash against ₹6.74 crores borrowings and a low debt-to-equity ratio (~0.04).
How does Gaudium IVF and Women Health Ltd rank vs peers in Healthcare Services?
Pro feature1Gaudium IVF and Women Health Ltd
Rev 2Mar 3
See full Healthcare Services sector rankings
How does Gaudium IVF and Women Health Ltd rank in Healthcare Services?
Compare Gaudium IVF and Women Health Ltd against every Healthcare Services company (Q1 FY27) on revenue, margins and earnings-call signals.